{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:32:09Z","timestamp":1789824729998,"version":"4.0.1"},"reference-count":54,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,31]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Cerliponase alfa is an enzyme replacement treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), administered via biweekly intracerebroventricular infusions. Typically, infusions are delivered via a head-sited access device; however, subcutaneously tunneled chest-sited devices could offer an alternative for improved ease of access and patient comfort. The aim of this study was to evaluate the safety, efficacy, and user experience of chest-sited versus head-sited intracerebroventricular access devices in patients with CLN2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This single-center prospective observational study included pediatric patients with CLN2 who received cerliponase alfa via intraventricular infusions using chest-sited and\/or head-sited devices. Incidents and complications, as well as access frequency, were documented over 1 year for both device types. Families and nurses were surveyed regarding sedation, distraction, access, securing, satisfaction, and device preference, and comparisons were made between chest-sited and head-sited devices regarding these factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Seventeen children (10 female, mean age 7.5 [SD 3.1] years) with CLN2 were included; 11 received chest-sited and 6 received head-sited devices. Families of 16 patients (10 with chest-sited and 6 with head-sited devices) completed the questionnaire. Sedation was required for 4 patients, 1 with a chest-sited device and 3 with head-sited devices. Distraction techniques, particularly singing and technology, were effective for 75% of patients who completed the family questionnaire. There was no significant difference in ease of access or securing between the two device types (p &gt; 0.9999) according to the families. However, nurses reported significantly easier access (p = 0.0308) and securing (p &lt; 0.0001) with chest-sited devices. Among patients who received both device types, 50% preferred chest-sited devices, 50% had no preference, and no patients preferred head-sited devices. Access success rates were higher for chest-sited devices (p = 0.0128), but device survival was comparable (p = 0.4492). The incident and complication rate was similar between groups, with no device-associated infections recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Chest-sited intracerebroventricular access devices for cerliponase alfa infusions offered benefits that included reduced sedation, easier access, better device securing, higher access success rates, and greater nursing satisfaction. Both devices had similar survival rates and incident and complication rates. Chest-sited devices can be considered a safe and effective alternative in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2025.7.peds25222","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:09:06Z","timestamp":1761962946000},"page":"87-94","source":"Crossref","is-referenced-by-count":4,"title":["Chest-sited intraventricular access devices for cerliponase alfa infusion in Batten disease at a single tertiary United Kingdom pediatric center"],"prefix":"10.3171","volume":"37","author":[{"given":"Jack","family":"Read","sequence":"first","affiliation":[{"name":"University of Exeter Medical School, Exeter;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Donald","sequence":"additional","affiliation":[{"name":"North of England Batten\u2019s Service, Royal Manchester Children\u2019s Hospital, Manchester;"},{"name":"Department of Neurosciences, University of Manchester; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Rhead","sequence":"additional","affiliation":[{"name":"North of England Batten\u2019s Service, Royal Manchester Children\u2019s Hospital, Manchester;"},{"name":"Department of Neurosciences, University of Manchester; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lervia","family":"Acquaah","sequence":"additional","affiliation":[{"name":"North of England Batten\u2019s Service, Royal Manchester Children\u2019s Hospital, Manchester;"},{"name":"Department of Neurosciences, University of Manchester; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Chan","sequence":"additional","affiliation":[{"name":"North of England Batten\u2019s Service, Royal Manchester Children\u2019s Hospital, Manchester;"},{"name":"Department of Neurosciences, University of Manchester; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Heap","sequence":"additional","affiliation":[{"name":"North of England Batten\u2019s Service, Royal Manchester Children\u2019s Hospital, Manchester;"},{"name":"Department of Neurosciences, University of Manchester; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Brown","sequence":"additional","affiliation":[{"name":"North of England Batten\u2019s Service, Royal Manchester Children\u2019s Hospital, Manchester;"},{"name":"Department of Neurosciences, University of Manchester; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunabha","family":"Ghosh","sequence":"additional","affiliation":[{"name":"North of England Batten\u2019s Service, Royal Manchester Children\u2019s Hospital, Manchester;"},{"name":"Department of Neurosciences, University of Manchester; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Allan","family":"Jones","sequence":"additional","affiliation":[{"name":"North of England Batten\u2019s Service, Royal Manchester Children\u2019s Hospital, Manchester;"},{"name":"Department of Neurosciences, University of Manchester; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipak","family":"Ram","sequence":"additional","affiliation":[{"name":"North of England Batten\u2019s Service, Royal Manchester Children\u2019s Hospital, Manchester;"},{"name":"Department of Neurosciences, University of Manchester; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Kamaly-Asl","sequence":"additional","affiliation":[{"name":"North of England Batten\u2019s Service, Royal Manchester Children\u2019s Hospital, Manchester;"},{"name":"The Geoffrey Jefferson Brain Research Centre, University of Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"Suppl 1","key":"b1","series-title":"Pediatr Endocrinol Rev","first-page":"682","article-title":"CLN2 disease (classic late infantile neuronal ceroid lipofuscinosis)","volume":"13","author":"Kohlsch\u00fctter A","year":"2016","unstructured":"Kohlsch\u00fctter A, Schulz A. CLN2 disease (classic late infantile neuronal ceroid lipofuscinosis). Pediatr Endocrinol Rev. 2016;13 Suppl 1:682\u2013688."},{"issue":"1","key":"b2","series-title":"Orphanet J Rare Dis","first-page":"185","article-title":"Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients","volume":"16","author":"Mole SE","year":"2021","unstructured":"Mole SE, Schulz A, Badoe E,  Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet J Rare Dis. 2021;16(1):185."},{"issue":"8","key":"b3","series-title":"Lancet Child Adolesc Health","first-page":"582","article-title":"Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study","volume":"2","author":"Nickel M","year":"2018","unstructured":"Nickel M, Simonati A, Jacoby D,  Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health. 2018;2(8):582\u2013590."},{"issue":"5","key":"b4","series-title":"Arch Dis Child","first-page":"361","article-title":"The epidemiology of progressive intellectual and neurological deterioration in childhood","volume":"95","author":"Verity C","year":"2010","unstructured":"Verity C, Winstone AM, Stellitano L, Will R, Nicoll A. The epidemiology of progressive intellectual and neurological deterioration in childhood. Arch Dis Child. 2010;95(5):361\u2013364."},{"issue":"1","key":"b5","series-title":"Lancet Neurol","first-page":"60","article-title":"Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study","volume":"23","author":"Schulz A","year":"2024","unstructured":"Schulz A, Specchio N, de Los Reyes E,  Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study. Lancet Neurol. 2024;23(1):60\u201370."},{"issue":"8","key":"b6","series-title":"J Child Neurol","first-page":"635","article-title":"Development of the \"Hamburg Best Practice Guidelines for ICV\u2212Enzyme Replacement therapy (ERT) in CLN2 Disease\" based on 6 years treatment experience in 48 patients","volume":"36","author":"Schwering C","year":"2021","unstructured":"Schwering C, Kammler G, Wibbeler E,  Development of the \"Hamburg Best Practice Guidelines for ICV\u2212Enzyme Replacement therapy (ERT) in CLN2 Disease\" based on 6 years treatment experience in 48 patients. J Child Neurol. 2021;36(8):635\u2013641."},{"issue":"1","key":"b7","series-title":"J Neurosurg Pediatr","first-page":"115","article-title":"A survival analysis of ventricular access devices for delivery of cerliponase alfa","volume":"29","author":"Craven CL","year":"2022","unstructured":"Craven CL, Gissen P, Bower R, Lee L, Aquilina K, Thompson DNP. A survival analysis of ventricular access devices for delivery of cerliponase alfa. J Neurosurg Pediatr. 2022;29(1):115\u2013121."},{"issue":"20","key":"b8","series-title":"N Engl J Med","first-page":"1898","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz A","year":"2018","unstructured":"Schulz A, Ajayi T, Specchio N,  Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med. 2018;378(20):1898\u20131907."},{"key":"b9","series-title":"Pediatr Neurol","first-page":"23","article-title":"Intracerebroventricular delivery as a safe, long-term route of drug administration","volume":"67","author":"Cohen-Pfeffer JL","year":"2017","unstructured":"Cohen-Pfeffer JL, Gururangan S, Lester T,  Intracerebroventricular delivery as a safe, long-term route of drug administration. Pediatr Neurol. 2017;67:23\u201335."},{"issue":"4","key":"b10","series-title":"J Neurosurg Pediatr","first-page":"409","article-title":"Indwelling intrathecal catheter with subcutaneous abdominal reservoir: a viable baclofen delivery system in severely cachectic patients","volume":"14","author":"Waqar M","year":"2014","unstructured":"Waqar M, Ellenbogen JR, Kumar R,  Indwelling intrathecal catheter with subcutaneous abdominal reservoir: a viable baclofen delivery system in severely cachectic patients. J Neurosurg Pediatr. 2014;14(4):409\u2013413."},{"issue":"3","key":"b11","series-title":"Expert Opin Emerg Drugs","first-page":"495","article-title":"Emerging drugs for lysosomal storage diseases","volume":"15","author":"Beck M","year":"2010","unstructured":"Beck M. Emerging drugs for lysosomal storage diseases. Expert Opin Emerg Drugs. 2010;15(3):495\u2013507."},{"issue":"1","key":"b12","series-title":"J Neurodev Disord","first-page":"16","article-title":"Recent progress and considerations for AAV gene therapies targeting the central nervous system","volume":"10","author":"Lykken EA","year":"2018","unstructured":"Lykken EA, Shyng C, Edwards RJ, Rozenberg A, Gray SJ. Recent progress and considerations for AAV gene therapies targeting the central nervous system. J Neurodev Disord. 2018;10(1):16."},{"issue":"2","key":"b13","series-title":"Brain Sci","first-page":"119","article-title":"Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases","volume":"10","author":"Perez BA","year":"2020","unstructured":"Perez BA, Shutterly A, Chan YK, Byrne BJ, Corti M. Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases. Brain Sci. 2020;10(2):119."},{"issue":"1","key":"b14","series-title":"J Transl Med","first-page":"53","article-title":"Brain-targeted delivery of neuroprotective survival gene minimizing hematopoietic cell contamination: implications for Parkinson\u2019s disease treatment","volume":"22","author":"Lee MH","year":"2024","unstructured":"Lee MH, Kang S, Um KH,  Brain-targeted delivery of neuroprotective survival gene minimizing hematopoietic cell contamination: implications for Parkinson\u2019s disease treatment. J Transl Med. 2024;22(1):53."},{"issue":"4","key":"b15","series-title":"Nat Med","first-page":"1001","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown CE","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D,  Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med. 2024;30(4):1001\u20131012."},{"issue":"2","key":"b16","series-title":"Mol Ther","first-page":"440","article-title":"Genetically modified ZIKA virus as a microRNA-sensitive oncolytic virus against central nervous system tumors","volume":"32","author":"Novaes GM","year":"2024","unstructured":"Novaes GM, Lima C, Longo C,  Genetically modified ZIKA virus as a microRNA-sensitive oncolytic virus against central nervous system tumors. Mol Ther. 2024;32(2):440\u2013456."},{"issue":"5402","key":"b17","series-title":"BMJ","first-page":"173","article-title":"A ventriculostomy reservoir","volume":"2","author":"Rickham PP","year":"1964","unstructured":"Rickham PP. A ventriculostomy reservoir. BMJ. 1964;2(5402):173\u2013173."},{"issue":"7315","key":"b18","series-title":"Lancet","first-page":"983","article-title":"Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid","volume":"2","author":"Ommaya AK","year":"1963","unstructured":"Ommaya AK. Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid. Lancet. 1963;2(7315):983\u2013984."},{"key":"b19","series-title":"Front Behav Neurosci","first-page":"54","article-title":"Touch perceptions across skin sites: differences between sensitivity, direction discrimination and pleasantness","volume":"8","author":"Ackerley R","year":"2014","unstructured":"Ackerley R, Carlsson I, Wester H, Olausson H, Backlund Wasling H. Touch perceptions across skin sites: differences between sensitivity, direction discrimination and pleasantness. Front Behav Neurosci. 2014;8:54."},{"issue":"9","key":"b20","series-title":"J Clin Med","first-page":"1847","article-title":"Current state of analgesia and sedation in the pediatric intensive care unit","volume":"10","author":"Egbuta C","year":"2021","unstructured":"Egbuta C, Mason KP. Current state of analgesia and sedation in the pediatric intensive care unit. J Clin Med. 2021;10(9):1847."},{"issue":"6","key":"b21","series-title":"JAMA Netw Open","first-page":"e2217427","article-title":"Anesthetic exposure during childhood and neurodevelopmental outcomes","volume":"5","author":"Reighard C","year":"2022","unstructured":"Reighard C, Junaid S, Jackson WM,  Anesthetic exposure during childhood and neurodevelopmental outcomes. JAMA Netw Open. 2022;5(6):e2217427."},{"issue":"5","key":"b22","series-title":"Pediatr Radiol","first-page":"724","article-title":"Safety challenges related to the use of sedation and general anesthesia in pediatric patients undergoing magnetic resonance imaging examinations","volume":"51","author":"Artunduaga M","year":"2021","unstructured":"Artunduaga M, Liu CA, Morin CE,  Safety challenges related to the use of sedation and general anesthesia in pediatric patients undergoing magnetic resonance imaging examinations. Pediatr Radiol. 2021;51(5):724\u2013735."},{"issue":"1","key":"b23","series-title":"Radiography (Lond)","first-page":"221","article-title":"Evaluation of distraction techniques for patients aged 4\u201310 years undergoing magnetic resonance imaging examinations","volume":"27","author":"Flattley R","year":"2021","unstructured":"Flattley R, Widdowfield M. Evaluation of distraction techniques for patients aged 4\u201310 years undergoing magnetic resonance imaging examinations. Radiography (Lond). 2021;27(1):221\u2013228."},{"issue":"6","key":"b24","series-title":"J Pediatr Nurs","first-page":"652","article-title":"Distraction techniques for children undergoing procedures: a critical review of pediatric research","volume":"27","author":"Koller D","year":"2012","unstructured":"Koller D, Goldman RD. Distraction techniques for children undergoing procedures: a critical review of pediatric research. J Pediatr Nurs. 2012;27(6):652\u2013681."},{"key":"b25","series-title":"Eur J Paediatr Neurol","first-page":"17","article-title":"Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: the first French cohort","volume":"30","author":"Estublier B","year":"2021","unstructured":"Estublier B, Cano A, Hoebeke C,  Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: the first French cohort. Eur J Paediatr Neurol. 2021;30:17\u201321."},{"issue":"6","key":"b26","series-title":"J Child Neurol","first-page":"468","article-title":"Cerliponase alfa for the treatment of atypical phenotypes of CLN2 disease: a retrospective case series","volume":"36","author":"Wibbeler E","year":"2021","unstructured":"Wibbeler E, Wang R, Reyes EL,  Cerliponase alfa for the treatment of atypical phenotypes of CLN2 disease: a retrospective case series. J Child Neurol. 2021;36(6):468\u2013474."},{"issue":"8","key":"b27","series-title":"J Pediatr Surg","first-page":"1427","article-title":"Central venous catheter consideration in pediatric oncology: a systematic review and meta-analysis from the American Pediatric Surgical Association Cancer Committee","volume":"59","author":"Christison-Lagay ER","year":"2024","unstructured":"Christison-Lagay ER, Brown EG, Bruny J,  Central venous catheter consideration in pediatric oncology: a systematic review and meta-analysis from the American Pediatric Surgical Association Cancer Committee. J Pediatr Surg. 2024;59(8):1427\u20131443."},{"issue":"Suppl 1","key":"b1","series-title":"Pediatr Endocrinol Rev","first-page":"682","article-title":"CLN2 disease (classic late infantile neuronal ceroid lipofuscinosis)","volume":"13","author":"Kohlsch\u00fctter A","year":"2016","unstructured":"Kohlsch\u00fctter A, Schulz A. CLN2 disease (classic late infantile neuronal ceroid lipofuscinosis). Pediatr Endocrinol Rev. 2016;13 Suppl 1:682\u2013688."},{"issue":"1","key":"b2","series-title":"Orphanet J Rare Dis","first-page":"185","article-title":"Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients","volume":"16","author":"Mole SE","year":"2021","unstructured":"Mole SE, Schulz A, Badoe E,  Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet J Rare Dis. 2021;16(1):185."},{"issue":"8","key":"b3","series-title":"Lancet Child Adolesc Health","first-page":"582","article-title":"Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study","volume":"2","author":"Nickel M","year":"2018","unstructured":"Nickel M, Simonati A, Jacoby D,  Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health. 2018;2(8):582\u2013590."},{"issue":"5","key":"b4","series-title":"Arch Dis Child","first-page":"361","article-title":"The epidemiology of progressive intellectual and neurological deterioration in childhood","volume":"95","author":"Verity C","year":"2010","unstructured":"Verity C, Winstone AM, Stellitano L, Will R, Nicoll A. The epidemiology of progressive intellectual and neurological deterioration in childhood. Arch Dis Child. 2010;95(5):361\u2013364."},{"issue":"1","key":"b5","series-title":"Lancet Neurol","first-page":"60","article-title":"Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study","volume":"23","author":"Schulz A","year":"2024","unstructured":"Schulz A, Specchio N, de Los Reyes E,  Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study. Lancet Neurol. 2024;23(1):60\u201370."},{"issue":"8","key":"b6","series-title":"J Child Neurol","first-page":"635","article-title":"Development of the \"Hamburg Best Practice Guidelines for ICV\u2212Enzyme Replacement therapy (ERT) in CLN2 Disease\" based on 6 years treatment experience in 48 patients","volume":"36","author":"Schwering C","year":"2021","unstructured":"Schwering C, Kammler G, Wibbeler E,  Development of the \"Hamburg Best Practice Guidelines for ICV\u2212Enzyme Replacement therapy (ERT) in CLN2 Disease\" based on 6 years treatment experience in 48 patients. J Child Neurol. 2021;36(8):635\u2013641."},{"issue":"1","key":"b7","series-title":"J Neurosurg Pediatr","first-page":"115","article-title":"A survival analysis of ventricular access devices for delivery of cerliponase alfa","volume":"29","author":"Craven CL","year":"2022","unstructured":"Craven CL, Gissen P, Bower R, Lee L, Aquilina K, Thompson DNP. A survival analysis of ventricular access devices for delivery of cerliponase alfa. J Neurosurg Pediatr. 2022;29(1):115\u2013121."},{"issue":"20","key":"b8","series-title":"N Engl J Med","first-page":"1898","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz A","year":"2018","unstructured":"Schulz A, Ajayi T, Specchio N,  Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med. 2018;378(20):1898\u20131907."},{"key":"b9","series-title":"Pediatr Neurol","first-page":"23","article-title":"Intracerebroventricular delivery as a safe, long-term route of drug administration","volume":"67","author":"Cohen-Pfeffer JL","year":"2017","unstructured":"Cohen-Pfeffer JL, Gururangan S, Lester T,  Intracerebroventricular delivery as a safe, long-term route of drug administration. Pediatr Neurol. 2017;67:23\u201335."},{"issue":"4","key":"b10","series-title":"J Neurosurg Pediatr","first-page":"409","article-title":"Indwelling intrathecal catheter with subcutaneous abdominal reservoir: a viable baclofen delivery system in severely cachectic patients","volume":"14","author":"Waqar M","year":"2014","unstructured":"Waqar M, Ellenbogen JR, Kumar R,  Indwelling intrathecal catheter with subcutaneous abdominal reservoir: a viable baclofen delivery system in severely cachectic patients. J Neurosurg Pediatr. 2014;14(4):409\u2013413."},{"issue":"3","key":"b11","series-title":"Expert Opin Emerg Drugs","first-page":"495","article-title":"Emerging drugs for lysosomal storage diseases","volume":"15","author":"Beck M","year":"2010","unstructured":"Beck M. Emerging drugs for lysosomal storage diseases. Expert Opin Emerg Drugs. 2010;15(3):495\u2013507."},{"issue":"1","key":"b12","series-title":"J Neurodev Disord","first-page":"16","article-title":"Recent progress and considerations for AAV gene therapies targeting the central nervous system","volume":"10","author":"Lykken EA","year":"2018","unstructured":"Lykken EA, Shyng C, Edwards RJ, Rozenberg A, Gray SJ. Recent progress and considerations for AAV gene therapies targeting the central nervous system. J Neurodev Disord. 2018;10(1):16."},{"issue":"2","key":"b13","series-title":"Brain Sci","first-page":"119","article-title":"Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases","volume":"10","author":"Perez BA","year":"2020","unstructured":"Perez BA, Shutterly A, Chan YK, Byrne BJ, Corti M. Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases. Brain Sci. 2020;10(2):119."},{"issue":"1","key":"b14","series-title":"J Transl Med","first-page":"53","article-title":"Brain-targeted delivery of neuroprotective survival gene minimizing hematopoietic cell contamination: implications for Parkinson\u2019s disease treatment","volume":"22","author":"Lee MH","year":"2024","unstructured":"Lee MH, Kang S, Um KH,  Brain-targeted delivery of neuroprotective survival gene minimizing hematopoietic cell contamination: implications for Parkinson\u2019s disease treatment. J Transl Med. 2024;22(1):53."},{"issue":"4","key":"b15","series-title":"Nat Med","first-page":"1001","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown CE","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D,  Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med. 2024;30(4):1001\u20131012."},{"issue":"2","key":"b16","series-title":"Mol Ther","first-page":"440","article-title":"Genetically modified ZIKA virus as a microRNA-sensitive oncolytic virus against central nervous system tumors","volume":"32","author":"Novaes GM","year":"2024","unstructured":"Novaes GM, Lima C, Longo C,  Genetically modified ZIKA virus as a microRNA-sensitive oncolytic virus against central nervous system tumors. Mol Ther. 2024;32(2):440\u2013456."},{"issue":"5402","key":"b17","series-title":"BMJ","first-page":"173","article-title":"A ventriculostomy reservoir","volume":"2","author":"Rickham PP","year":"1964","unstructured":"Rickham PP. A ventriculostomy reservoir. BMJ. 1964;2(5402):173\u2013173."},{"issue":"7315","key":"b18","series-title":"Lancet","first-page":"983","article-title":"Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid","volume":"2","author":"Ommaya AK","year":"1963","unstructured":"Ommaya AK. Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid. Lancet. 1963;2(7315):983\u2013984."},{"key":"b19","series-title":"Front Behav Neurosci","first-page":"54","article-title":"Touch perceptions across skin sites: differences between sensitivity, direction discrimination and pleasantness","volume":"8","author":"Ackerley R","year":"2014","unstructured":"Ackerley R, Carlsson I, Wester H, Olausson H, Backlund Wasling H. Touch perceptions across skin sites: differences between sensitivity, direction discrimination and pleasantness. Front Behav Neurosci. 2014;8:54."},{"issue":"9","key":"b20","series-title":"J Clin Med","first-page":"1847","article-title":"Current state of analgesia and sedation in the pediatric intensive care unit","volume":"10","author":"Egbuta C","year":"2021","unstructured":"Egbuta C, Mason KP. Current state of analgesia and sedation in the pediatric intensive care unit. J Clin Med. 2021;10(9):1847."},{"issue":"6","key":"b21","series-title":"JAMA Netw Open","first-page":"e2217427","article-title":"Anesthetic exposure during childhood and neurodevelopmental outcomes","volume":"5","author":"Reighard C","year":"2022","unstructured":"Reighard C, Junaid S, Jackson WM,  Anesthetic exposure during childhood and neurodevelopmental outcomes. JAMA Netw Open. 2022;5(6):e2217427."},{"issue":"5","key":"b22","series-title":"Pediatr Radiol","first-page":"724","article-title":"Safety challenges related to the use of sedation and general anesthesia in pediatric patients undergoing magnetic resonance imaging examinations","volume":"51","author":"Artunduaga M","year":"2021","unstructured":"Artunduaga M, Liu CA, Morin CE,  Safety challenges related to the use of sedation and general anesthesia in pediatric patients undergoing magnetic resonance imaging examinations. Pediatr Radiol. 2021;51(5):724\u2013735."},{"issue":"1","key":"b23","series-title":"Radiography (Lond)","first-page":"221","article-title":"Evaluation of distraction techniques for patients aged 4\u201310 years undergoing magnetic resonance imaging examinations","volume":"27","author":"Flattley R","year":"2021","unstructured":"Flattley R, Widdowfield M. Evaluation of distraction techniques for patients aged 4\u201310 years undergoing magnetic resonance imaging examinations. Radiography (Lond). 2021;27(1):221\u2013228."},{"issue":"6","key":"b24","series-title":"J Pediatr Nurs","first-page":"652","article-title":"Distraction techniques for children undergoing procedures: a critical review of pediatric research","volume":"27","author":"Koller D","year":"2012","unstructured":"Koller D, Goldman RD. Distraction techniques for children undergoing procedures: a critical review of pediatric research. J Pediatr Nurs. 2012;27(6):652\u2013681."},{"key":"b25","series-title":"Eur J Paediatr Neurol","first-page":"17","article-title":"Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: the first French cohort","volume":"30","author":"Estublier B","year":"2021","unstructured":"Estublier B, Cano A, Hoebeke C,  Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: the first French cohort. Eur J Paediatr Neurol. 2021;30:17\u201321."},{"issue":"6","key":"b26","series-title":"J Child Neurol","first-page":"468","article-title":"Cerliponase alfa for the treatment of atypical phenotypes of CLN2 disease: a retrospective case series","volume":"36","author":"Wibbeler E","year":"2021","unstructured":"Wibbeler E, Wang R, Reyes EL,  Cerliponase alfa for the treatment of atypical phenotypes of CLN2 disease: a retrospective case series. J Child Neurol. 2021;36(6):468\u2013474."},{"issue":"8","key":"b27","series-title":"J Pediatr Surg","first-page":"1427","article-title":"Central venous catheter consideration in pediatric oncology: a systematic review and meta-analysis from the American Pediatric Surgical Association Cancer Committee","volume":"59","author":"Christison-Lagay ER","year":"2024","unstructured":"Christison-Lagay ER, Brown EG, Bruny J,  Central venous catheter consideration in pediatric oncology: a systematic review and meta-analysis from the American Pediatric Surgical Association Cancer Committee. J Pediatr Surg. 2024;59(8):1427\u20131443."}],"container-title":["Journal of Neurosurgery: Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-pediatr\/37\/1\/article-p87.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-pediatr\/37\/1\/article-p87.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-pediatr\/37\/1\/article-p87.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:46:22Z","timestamp":1772804782000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-pediatr\/37\/1\/article-p87.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":54,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3171\/2025.7.peds25222","relation":{},"ISSN":["1933-0707","1933-0715"],"issn-type":[{"value":"1933-0707","type":"print"},{"value":"1933-0715","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]}}}